CHAPS hydrate | 331717-45-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: CHAPS hydrate
• 英文别名: 3-[dimethyl-[3-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]propane-1-sulfonate;hydrate
• CAS: 331717-45-4
• 化学式: C32H60N2O8S
• 分子量: 632.9
• InChiKey: SJCUTFKCLFLIFE-JWTJKVBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  43
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  156
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] COMPOUNDS ACTIVE TOWARDS BROMODOMAINS<br/>[FR] COMPOSÉS ACTIFS ENVERS DES BROMODOMAINES
  申请人：NUEVOLUTION AS

  公开号：WO2016016316A1

  公开（公告）日：2016-02-04

  Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

  揭示了针对溴结构域的化合物，含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
• DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY
  申请人：Jacobson Kenneth A.

  公开号：US20090012035A1

  公开（公告）日：2009-01-08

  Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A 1 adenosine receptor agonist having a purine nucleoside moiety and a functional group at the N 6 position of the purine nucleoside moiety, wherein the functional group has the formula (I): N 6 H—Ar 1 —CH 2 —C(═O)NH—R 1 (I), wherein Ar 1 and R 1 as defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.

  本文披露了包含树状聚合物和配体的共轭物，其中配体是G-蛋白偶联受体（GPCR）超家族受体的激动剂或拮抗剂的官能化同系物，例如，其中官能化同系物是具有嘌呤核苷酸基团和在嘌呤核苷酸基团的N6位置上具有官能基的A1腺苷受体激动剂，其中官能基具有以下结构式（I）：N6H—Ar1—CH2—C(═O)NH—R1（I），其中Ar1和R1如本文所定义。还披露了包括制药组合物、治疗各种疾病的方法以及使用这种共轭物的诊断方法。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU RÉCEPTEUR APPARENTÉ AU RÉCEPTEUR DES RÉTINOÏDES (ROR) GAMMA-T
  申请人：UNIV EINDHOVEN TECH

  公开号：WO2020149740A1

  公开（公告）日：2020-07-23

  The present invention relates to the field of (auto)immune diseases. The present invention provides heterocyclic compounds having an ROR-yt inhibitory action. It also provides for the use of the compounds as a medicament, in particular for use in the treatment of (auto)immune diseases. Also provided are pharmaceutical compositions comprising the compounds having ROR-yt inhibitory action.

  本发明涉及（自动）免疫疾病领域。本发明提供具有ROR-yt抑制作用的杂环化合物。还提供了将这些化合物用作药物的用途，特别是用于治疗（自动）免疫疾病。还提供了包含具有ROR-yt抑制作用的化合物的药物组合物。
• HEMATOPOIETIC NEOPLASM CHEMOTHERAPY
  申请人：Eli Lilly and Company

  公开号：US20140235621A1

  公开（公告）日：2014-08-21

  A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.

  提供一种治疗混合谱系白血病的方法和药物；转位混合谱系白血病；基于转位混合谱系白血病的急性髓性白血病；基于转位混合谱系白血病的急性淋巴细胞白血病；非MLL基础的慢性髓增生性疾病或非MLL基础的急性淋巴细胞白血病的方法和药物。
• 2,7-DISUBSTITUTED CEPHALOSPORIN DERIVATIVES AS BETA-LACTAMASE SUBSTRATES AND METHODS FOR THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS
  申请人：The Texas A&M University System

  公开号：US20150219653A1

  公开（公告）日：2015-08-06

  β-Lactamase substrates and methods for using the substrates to detect β-lactamase and to diagnose tuberculosis.

  β-内酰胺酶底物及其使用方法，用于检测β-内酰胺酶并诊断结核病。